Is Your DNA the Key to Beating Cancer? Exploring the Role of Genetic Testing in Cancer Care

By-Dr Chandrasekhar Prasad Singh, Consultant – Medical Oncology, HCG Abdur Razzaque Ansari Cancer Centre, Ranchi

Despite remarkable advancements in medicine, cancer remains one of the most challenging diseases to treat, with each patient responding differently to therapy. While lifestyle and environmental factors contribute to its development, our DNA holds crucial insights about cancer risk, progression, and treatment effectiveness.

Advances in genetic testing are now revolutionizing cancer care, helping to predict risk, tailor treatments, and even prevent cancer before it starts. But how exactly does genetic testing work, and can it truly be the key to beating cancer?

What Is Genetic Testing in Cancer Care?

Genetic testing analyzes a person’s DNA to identify mutations or inherited traits that may increase cancer risk. These tests can be performed on:

• Germline DNA– The genes inherited from parents, which can indicate a hereditary risk for cancer.
• Tumor DNA– Genetic changes in cancer cells that help determine treatment options.

By identifying specific mutations, doctors can take a more personalized approach to prevention, early detection, and treatment, improving patient outcomes.

How Can Genetic Testing Help in Cancer Treatment?

Identifying High-Risk Individuals

• Some people carry genetic mutations that predispose them to cancer, such as BRCA1 and BRCA2 for breast and ovarian cancer or MLH1 and MSH2 for colorectal cancer. Knowing this allows for early screenings and preventive measures.

Personalized Treatment Plans

• Genetic testing helps doctors choose targeted therapies that are more effective for a patient’s specific cancer type. For example, HER2-positive breast cancer responds to targeted drugs like trastuzumab (Herceptin), while lung cancer patients with EGFR mutations may benefit from specific inhibitors.

Predicting Treatment Response

• Certain genetic markers can indicate whether a patient will respond well to chemotherapy, immunotherapy, or radiation, helping to avoid ineffective treatments and reduce side effects.

Guiding Family Health Decisions

• If a person carries a hereditary cancer mutation, family members can also be tested, allowing them to take proactive health measures such as increased screenings or lifestyle changes.

Types of Genetic Tests in Cancer Care

There are different types of genetic tests, depending on their purpose:

• Predictive Genetic Testing– Identifies inherited gene mutations that increase cancer risk before any symptoms appear.
• Diagnostic Genetic Testing– Helps confirm a cancer diagnosis by identifying specific mutations in tumor cells.
• Pharmacogenomic Testing– Determines how a patient’s genes affect their response to medications, ensuring the most effective treatment is chosen.

Who Should Consider Genetic Testing?

Genetic testing isn’t necessary for everyone, but it may be recommended if:

• You have a strong family history of cancer(such as multiple relatives with the same type of cancer).
• You were diagnosed with cancer at a young age(such as breast or colorectal cancer before 50).
• You have an unusual or rare cancer(like male breast cancer or multiple types of cancer).
• Your ancestry is linked to higher genetic risk(e.g., Ashkenazi Jewish descent has a higher prevalence of BRCA mutations).

The Future of Genetic Testing in Cancer Care

With advancements in genomic medicine, genetic testing is expected to become even more precise, accessible, and impactful. Researchers are exploring gene-editing technologies like CRISPR to correct faulty genes, and ongoing studies continue to expand our understanding of how genetic mutations drive cancer progression.

Final Thoughts: Is DNA the Key to Beating Cancer?

While genetic testing isn’t a cure for cancer, it is one of the most powerful tools available for early detection, prevention, and personalized treatment. By unlocking the secrets within our DNA, we move closer to a future where cancer is not just treatable, but preventable. If you have concerns about hereditary cancer risk, consulting a genetic counselor could be the first step toward a proactive and personalized approach to your health.

Hungama OTT Marks New Chapter With Rebranding and Unveiling of 24-Show Slate at Exclusive Success Party

Mumbai, 07th May 2025 – Hungama OTT, one of India’s most popular digital entertainment platforms, formerly known as Hungama, hosted an exclusive success party on 05th May 2025 at Luuma House, Juhu, to mark a bold new chapter in its journey. The event celebrated the brand’s dynamic rebranding to ‘Hungama OTT’, the expansion of the Hungama OTT app—now available on smart TVs and connected devices, and the unveiling of a bold new content slate featuring 24 original shows across diverse genres, reaffirming its commitment to compelling storytelling. The celebration brought together key figures from the entertainment industry, including Monalisa, Amruta Khanvilkar, Divya Agarwal, Tina Dutta, Gulki Joshi, Yukti Kapoor, Akanksha Puri, among others, marking a significant milestone in the platform’s growth journey.

The celebration highlighted Hungama OTT’s impressive run since its September 2024 content showcase. Many of the shows announced then, such as Flight Attendant, Checkmate, Personal Trainer, Red Room, Pyramid, Pati Patni aur Padosan, Hasratein 2, and Khadaan, have emerged as fan favourites, trending across platforms and garnering critical acclaim. Continuing that momentum, the 2025 slate introduces fresh originals such as Mona ki Monohar Kahaniyaan, Judwa Jaal, Rose Garden, Chakravyuh, Badass begum, Blind Game, Balance show, Hungama Hone Do, Shaadi Ki Uss Raat, Takshika, Girl Scams, Room Service, Bollywood Murder, Hasratein season 3, and Ratri Ke Yatri season 3, promising an eclectic mix of thrillers, dramas, romances, and experimental formats. With the introduction of the Hungama OTT TV app, viewers can now experience this content on a more personalized, intuitive platform, bridging tech and storytelling.

Neeraj Roy, Founder & Managing Director, Hungama Digital Media, said, “Hungama OTT is focussed on delivering compelling and engaging shows with a strong commitment to storytelling. We’re launching an ambitious slate of 24 original shows in a year spanning drama, thrillers and more. while we’ve always been on your phones, we’re now coming into your living rooms. With a new Hungama OTT TV App, we’re bringing our content to the big screen offering a deeper, more immersive viewing experience. This is not just growth, it’s a bold leap into the future shaped entirely around our core audience.”

AIMIL Animal Health celebrated World Veterinary Day 2025 with nationwide virtual Continuing Veterinary Education (e-CVE) program

New Delhi, 6th May 2025

AIMIL Animal Health, the veterinary division of AIMIL Pharmaceuticals (India) Ltd, observed World Veterinary Day 2025 by organizing a large-scale virtual Continuing Veterinary Education (e-CVE) program. The online event was attended by over 3,000 participants which includes veterinary students, clinicians, research scholars, practicing clinicians, para vets, the Field staff and members of Allied profession. from across India and abroad, to explore the role of holistic and herbal approaches in animal healthcare.

The session was inaugurated by Dr. Sujit Kumar Dutta, Joint Commissioner at the National Livestock Mission, Department of Animal Husbandry & Dairying, Government of India. In his keynote address, Dr. Dutta highlighted the importance of adopting integrative veterinary practices and acknowledged AIMIL’s contribution to promoting Ayurveda-based animal care. “Initiatives like this are crucial in encouraging young professionals to consider sustainable and holistic models of veterinary treatment,” he said.

The event featured presentations by several experts from diverse fields within veterinary science. Dr. Narayan Dutta of the Indian Veterinary Research Institute (IVRI) discussed the link between nutrition and animal productivity. Mr. Venkat Gollapudi, Project Head at AIMIL, shared the company’s ongoing projects in veterinary research. Dr. N.K. Mahajan focused on liver and kidney issues in poultry, while Dr. Vikas from CGS Hospital, Gurugram, presented on herbal treatments in canine care. Dr. Daniel Mateuta Sirbu Daniel , the international speaker from UAE spoke on integrative care for exotic species. Dr. K. Raj Kumar of RIVER, Pondicherry, addressed advancements in companion animal care, and Dr. Ujjwal Kr De (IVRI) outlined approaches for managing mastitis in cattle. Dr. Jaya Krushna Das from OUAT, Odisha, provided insights into livestock reproductive health.

At the helm of this initiative was Dr. Ikshit Sharma, Executive Director of AIMIL Pharmaceuticals, whose visionary leadership continues to guide AIMIL’s mission to enhance the well-being of animals and improve the livelihood of farmers and common individuals in the animal husbandry sector. Dr Sharma said the company aims to combine traditional systems of medicine with modern veterinary science. He spoke about the need for herbal veterinary alternatives that align with the One Health approach of the World Health Organization. He also noted the potential of phytobiotics and other non-antibiotic solutions in managing animal health.

The program received registrations from more than 3,000 participants, with 55 percent being veterinary students and the rest comprising field veterinarians, para-vets, and practitioners. Students from 47 veterinary colleges took part in academic activities, including a national quiz competition with 579 entries, 200 poster presentations, 51 thesis submissions, and 89 clinical case studies. Selected entries were awarded prizes, and all participants received appreciation hampers.

The Participants & prize winners of the various contests were appreciated by Honorable Founder and Managing Director of AIMIL Pharmaceuticals, Shri K K Sharma. The program was coordinated by Dr. Anil Kr Sharma and Dr. T.S. Easwari, Vice President at AIMIL, while Dr. Rajan Handa, General Manager, AIMIL Animal Health, delivered the vote of thanks. The organizers noted that veterinary health is a shared responsibility and called for stronger collaboration across the sector.

AIMIL Animal Health is known for its research-based herbal veterinary formulations used in the care of poultry, livestock, and companion animals. The division’s recent technology transfer from the Indian Veterinary Research Institute for a cattle feed supplement is expected to support further innovation and led to further product range expansion in livestock nutrition,poultry feed supplement, pet food and aquaculture.

Viva ACP Launches Bricklyn – Where Timeless Strength Meets Modern Innovation

Viva, Asia’s largest manufacturer and supplier of aluminium composite panels (ACP), has been at the forefront of innovation in the cladding industry since 2003, continuously pushing boundaries with cutting-edge technology and design. We are proud to introduce Bricklyn, an exciting new addition to our Santa Fe series. Inspired by the enduring strength of traditional bricks and reimagined with a contemporary twist, Bricklyn is a fusion of heritage and modernity, bringing together classic construction aesthetics with advanced engineering.

Drawing inspiration from the dynamic energy of Brooklyn and the ingenious stacking design of Jenga, Bricklyn reinvents the timeless appeal of bricks into a stylish and durable ACP series. Designed to offer both structural integrity and aesthetic versatility, it creates visually striking façades while ensuring long-lasting performance. Each panel seamlessly fits together, forming walls that exude strength while allowing creative freedom in design.

Bricklyn is available in a stunning palette, ranging from beautiful soft muted tones to deep, rich hues, allowing architects and designers to craft elegant and dynamic exteriors. Whether creating a warm, earthy look or a bold, modern statement, this versatile colour selection enhances the visual appeal of any structure while maintaining a natural aesthetic.

Crafted using Stucco Textures and Synchro Technology, Bricklyn is engineered for durability and resilience, making it an ideal choice for contemporary architectural projects. With a 15-year warranty, this series guarantees quality and longevity, reinforcing Viva ACP’s commitment to excellence.

Bricklyn is more than just a cladding solution; it is a celebration of tradition, technology, and transformative design. With this latest innovation, Viva ACP continues to set new benchmarks in architectural possibilities, enabling designers and architects to bring their boldest visions to life.

Shriram Mobility Bulletin, May 2025

Hyderabad, May 6th, 2025: The Shriram Mobility Bulletin released today reveals that truck rentals remained largely flat in April 2025, despite a 5-10% hike in toll charges across various routes. A rise in goods movement, coupled with movement of summer fruits contributed to a subtle positive undercurrent in the freight market.

Truck rentals on most key trunk routes remained unchanged. The Delhi–Chennai–Delhi corridor saw a sharp MoM increase of 2.5%, while the Delhi–Bengaluru–Delhi route recorded a decline of 1.6%. On a year-on-year (YoY) basis, truck rentals posted healthy growth — with the Kolkata–Guwahati–Kolkata route rising 14%, and the Mumbai–Chennai–Mumbai corridor up 8%.

Rural demand and improved connectivity led to a 12% MoM rise in two-wheeler sales. Bus sales grew 4%, continuing momentum from March’s all-time high. E-rickshaws with carts saw the strongest YoY growth at 77%. However, lower-than-expected government infrastructure spending impacted monthly commercial vehicle sales: tractors declined 13%, construction equipment 9%, and earth-moving equipment 19% MoM.

The electric vehicle (EV) segment showed mixed signals. While EV three-wheeler sales rose by 5% MoM, EV two-wheeler sales dropped sharply by 30%, and EV car sales declined by 4%. Despite these short-term setbacks, YoY comparisons were robust: EV cars grew by 58%, three-wheelers by 49%, and two-wheelers by 40%.

Mr. Y S Chakravarti, CEO and Managing Director, Shriram Finance Ltd. said, “Truck rentals remained subdued during April despite a 5 to 10% increase in toll charges from April 1. The undercurrent however turned slightly better as the just concluded Rabi season was good. With the summer heat waves predicted, trucking activity could get slightly impacted.”

Petrol consumption declined by 2% in April, whereas diesel consumption increased by 2% MoM, driven by higher industrial, mining, and commercial activity. FASTag transaction volumes grew by 0.9%, while the transaction value edged up by 0.03% MoM.

Salaam Namaste Receives National Award at WAVES 2025

Noida: During the 8th National Community Radio Sammelan held in Mumbai as part of WAVES 2025, the winners of the 10th National Community Radio Awards were announced. Community radio station Salaam Namaste received the Third Prize for Most Innovative Community Engagement. The award was presented for the radio program “Maid Didi”.Union Minister of State for Information & Broadcasting, Dr. L. Murugan, presented the trophy, certificate, and cash prize to Barsha Chabaria, Station Head of Salaam Namaste, during the event.

Barsha Chabaria stated that Salaam Namaste is the first community radio station in Uttar Pradesh to have received the national award four times. This year, it is also the only community radio station from the state to be honored. She explained that the “Maid Didi” program is aimed at connecting domestic helpers with new skills and training, helping them gain social recognition. The program was inaugurated by Hon’ble Prime Minister Shri Narendra Modi.The award ceremony was graced by dignitaries including Union Minister Dr. L. Murugan and Dr. Anupama Bhatnagar, Vice Chancellor of IIMC.

Expressing his pride on Salaam Namaste’s achievement, IMS President Rajeev Kumar Gupta said that this success of Salaam Namaste Community Radio is not only a matter of pride for the institution but also reflects its commitment and dedication to society. Vice President Chirag Gupta added that they are proud of the unique identity their radio channel has created at the national level in the field of community engagement. This achievement is an inspiration for the entire IMS family, and they will continue to support such innovative efforts.

Professor Dr. Vikas Dhawan, Director General of the institution, congratulated the team of Salaam Namaste, saying that this accomplishment reflects the institute’s social commitment and values. He praised the platform for consistently empowering the voice of the common people and expressed his confidence that the team would continue to work with the same enthusiasm and energy.

This Mother’s Day, Let Love Take Center Stage at The Square, Novotel Pune

This Mother’s Day, step away from the ordinary and into a world where love is plated with care, memories are made around the table, and every detail whispers, “Thank you, Mom.”

The Square at Novotel Pune invites you to celebrate the heart of your family with a lavish brunch experience designed to delight, indulge, and honour the irreplaceable bond between a mother and her loved ones.

From elegant entrees and live gourmet stations to decadent desserts and effervescent pours, every moment is crafted with warmth and grace — just like she’s always done for you.

SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla

Mumbai, May 6, 2025 – SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announced today that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla from Serum Institute of India (SII). SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the company.

With deep healthcare investing experience and local expertise in India, having TPG join the partnership alongside SCHOTT Pharma and Serum Institute of India represents a significant milestone in SCHOTT Poonawalla’s growth, equipping the company with additional resources and strategic insight to support its long-term global ambitions.

SCHOTT Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company’s portfolio features a large range of products including cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and Contract Development and Manufacturing Organizations (CDMOs).

“We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla’s market leadership position as India’s largest injectables-focused drug containment solutions company,” said Bhushan Bopardikar, Business Unit Partner at TPG Growth. “On the back of a world-class manufacturing infrastructure in India, SCHOTT Poonawalla has developed an industry leading reputation by offering a comprehensive product portfolio of the highest quality for over two decades. We look forward to partnering with the senior leadership team as they continue to innovate and improve the quality and standards of pharmaceutical drug containment solutions.”

“Partnering with TPG marks an important step for us,” said Adar Poonawalla, CEO of Serum Institute of India. “Their experience in healthcare investing and global network make them a strong partner as we scale and explore new opportunities. Our collaboration with SCHOTT Pharma will continue, ensuring supply chain resilience and advancing innovation in vaccine packaging and delivery.”

“India continues to be one of the most dynamic and strategically important manufacturing hubs for SCHOTT Pharma. Welcoming TPG to the partnership marks an exciting step forward in our collaboration. SCHOTT Pharma’s innovation capabilities and pure-play focus on injectables will be complemented by TPG’s local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector. As we continue to expand our local production capacities and leading role in the Indian market, we are confident that this step will further enhance our global footprint and deliver exceptional value to our customers,” said Andreas Reisse, CEO at SCHOTT Pharma.

“Now more than ever, our pharmaceutical customers are relying on us to supply next-generation cutting-edge drug delivery solutions, as they continue to innovate, expand operations and supply complex drugs,” said Ashok Saxena, Managing Director, SCHOTT Poonawalla. “We are excited to welcome TPG onboard as an investor, and are confident that their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla.”